{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:56:43Z","timestamp":1792612603821,"version":"4.5.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2009,6,20]],"date-time":"2009-06-20T00:00:00Z","timestamp":1245456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s00228-009-0678-8","type":"journal-article","created":{"date-parts":[[2009,6,19]],"date-time":"2009-06-19T07:15:23Z","timestamp":1245395723000},"page":"757-773","source":"Crossref","is-referenced-by-count":258,"title":["Pharmacokinetics and dosage adjustment in patients with renal dysfunction"],"prefix":"10.1007","volume":"65","author":[{"given":"Roger K.","family":"Verbeeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora T.","family":"Musuamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,6,20]]},"reference":[{"key":"678_CR1","first-page":"1787","volume-title":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics","author":"KE Thummel","year":"2006","unstructured":"Thummel KE, Shen DD, Isoherranen N, Smith HE (2006) Design and optimization of dosage regimens: pharmacokinetic data. In: Brunton LL, Lazo LL, Parker KL (eds) Goodman & Gilman\u2019s The pharmacological basis of therapeutics, 11 edn. McGraw-Hill, New York, pp 1787\u20131888","edition":"11"},{"key":"678_CR2","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","volume":"298","author":"J Coresh","year":"2007","unstructured":"Coresh J, Selvin E, Stevens LA et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298:2038\u20132047","journal-title":"JAMA"},{"key":"678_CR3","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.4065\/83.9.1064","volume":"83","author":"JW Graves","year":"2008","unstructured":"Graves JW (2008) Diagnosis and management of chronic kidney disease. Mayo Clin Proc 83:1064\u20131069","journal-title":"Mayo Clin Proc"},{"key":"678_CR4","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","volume":"354","author":"LA Stevens","year":"2006","unstructured":"Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function\u2014measured and estimated glomerular filtration rate. N Engl J Med 354:2473\u20132483","journal-title":"N Engl J Med"},{"key":"678_CR5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2165\/00003088-200342140-00002","volume":"42","author":"SE Tett","year":"2003","unstructured":"Tett SE, Kirkpatrick CMJ, Gross AS, McLachlan AJ (2003) Principles and clinical application of assessing alterations in renal elimination pathways. Clin Pharmacokinet 42:1193\u20131211","journal-title":"Clin Pharmacokinet"},{"key":"678_CR6","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/ndt\/gfn028","volume":"23","author":"PE Jong de","year":"2008","unstructured":"de Jong PE, Gansevoort RT (2008) Fact or fiction of the epidemic of chronic kidney disease\u2014let us not squabble about estimated GFR only, but also focus on albuminuria. Nephrol Dial Transplant 23:1092\u20131095","journal-title":"Nephrol Dial Transplant"},{"key":"678_CR7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00041552-199811000-00009","volume":"7","author":"F Gaspari","year":"1998","unstructured":"Gaspari F, Perico N, Remuzzi G (1998) Application of newer clearance techniques for the determination of glomerular filtration rate. Curr Opin Nephrol Hypertens 7:675\u2013680","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"678_CR8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockroft","year":"1976","unstructured":"Cockroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341","journal-title":"Nephron"},{"key":"678_CR9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461\u2013470","journal-title":"Ann Intern Med"},{"key":"678_CR10","first-page":"A0828","volume":"11","author":"AS Levey","year":"2000","unstructured":"Levey AS, Greene T, Kusk JW, Beck GJ, MDRD Study Group (2000) A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:A0828 (Abstract)","journal-title":"J Am Soc Nephrol"},{"key":"678_CR11","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1097\/01.ASN.0000022011.35035.F3","volume":"13","author":"AG Bostom","year":"2002","unstructured":"Bostom AG, Kronenberg F, Eberhard R (2002) Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 13:2140\u20132144","journal-title":"J Am Soc Nephrol"},{"key":"678_CR12","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1097\/00003246-199310000-00016","volume":"21","author":"S Robert","year":"1993","unstructured":"Robert S, Zarowitz BJ, Peterson EL, Dumler F (1993) Predictability of creatinine clearance estimates in critically ill patients. Crit Care Med 21:1487\u20131495","journal-title":"Crit Care Med"},{"key":"678_CR13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1046\/j.1365-2125.1999.00938.x","volume":"47","author":"CM Kirkpatrick","year":"1999","unstructured":"Kirkpatrick CM, Duffull SB, Begg EJ (1999) Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 47:637\u2013643","journal-title":"Br J Clin Pharmacol"},{"key":"678_CR14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2125.2007.02917.x","volume":"63","author":"JK Aronson","year":"2007","unstructured":"Aronson JK (2007) Drug therapy in kidney diesease. Br J Clin Pharmacol 63:509\u2013511","journal-title":"Br J Clin Pharmacol"},{"key":"678_CR15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.clinbiochem.2006.10.014","volume":"40","author":"S Herget-Rosenthal","year":"2007","unstructured":"Herget-Rosenthal S, B\u00f6kenkamp A, Hofmann W (2007) How to estimate GFR\u2014serum creatinine, serum cystatin C or equations? Clin Biochem 40:153\u2013161","journal-title":"Clin Biochem"},{"key":"678_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinbiochem.2004.09.025","volume":"38","author":"G Filler","year":"2005","unstructured":"Filler G, B\u00f6kenkamp A, Hofmann W, Lebricon T, Martinez-Bru C, Grubb A (2005) Cystatin C as a marker of GFR\u2014history, indications, and future research. Clin Biochem 38:1\u20138","journal-title":"Clin Biochem"},{"key":"678_CR17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/MNH.0b013e3282fb77f2","volume":"17","author":"DF Work","year":"2008","unstructured":"Work DF, Schwartz GJ (2008) Estimating and measuring glomerular filtration rate in children. Curr Opin Nephrol Hypertens 17:320\u2013325","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"678_CR18","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/ndt\/gfh839","volume":"20","author":"NL Proulx","year":"2005","unstructured":"Proulx NL, Akbari A, Garg AX, Rostom A, Jaffey J, Clark HD (2005) Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis. Nephrol Dial Transplant 20:1617\u20131622","journal-title":"Nephrol Dial Transplant"},{"key":"678_CR19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2125.2007.03073.x","volume":"64","author":"DG Waller","year":"2007","unstructured":"Waller DG (2007) Drugs and the kidney: more than a question of dose. Br J Clin Pharmacol 64:719\u2013721","journal-title":"Br J Clin Pharmacol"},{"key":"678_CR20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00003088-200746080-00004","volume":"46","author":"DA Sica","year":"2007","unstructured":"Sica DA (2007) Considerations in drug handling in renal disease. Clin Pharmacokinet 46:677\u2013679","journal-title":"Clin Pharmacokinet"},{"key":"678_CR21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.clpt.6100050","volume":"81","author":"A Fuhr","year":"2007","unstructured":"Fuhr A, Jetter A, Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the \u201ecocktail\u201c approach. Clin Pharmacol Ther 81:270\u2013283","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2125.2001.01390.x","volume":"51","author":"AS Gross","year":"2001","unstructured":"Gross AS, MacLachlan AJ, Minns I et al (2001) Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. Br J Clin Pharmacol 51:547\u2013555","journal-title":"Br J Clin Pharmacol"},{"key":"678_CR23","unstructured":"Tozer TN, Rowland M (2006) Introduction to pharmacokinetics and pharmacodynamics: the quantitative basis of drug therapy. Lippincott Williams & Williams, Philadelphia, pp 97\u2013100"},{"key":"678_CR24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.pharmtox.44.101802.121856","volume":"44","author":"W Lee","year":"2004","unstructured":"Lee W, Kim B (2004) Transporters and renal elimination. Annu Rev Pharmacol Toxicol 44:137\u2013166","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"678_CR25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejphar.2008.02.085","volume":"585","author":"AAK El-Sheikh","year":"2008","unstructured":"El-Sheikh AAK, Masereeuw R, Russel FGM (2008) Mechanisms of renal anionic transport. Eur J Pharmacol 585:245\u2013255","journal-title":"Eur J Pharmacol"},{"key":"678_CR26","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11095-007-9254-z","volume":"24","author":"H Koepell","year":"2007","unstructured":"Koepell H, Lips K, Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227\u20131251","journal-title":"Pharm Res"},{"key":"678_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)06653-0","volume":"39","author":"GR Wilkinson","year":"1987","unstructured":"Wilkinson GR (1987) Clearance approaches in pharmacology. Pharmacol Rev 39:1\u201347","journal-title":"Pharmacol Rev"},{"key":"678_CR28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/138920006774832604","volume":"7","author":"A Baumann","year":"2006","unstructured":"Baumann A (2006) Early development of therapeutic biologics\u2014pharmacokinetics. Curr Drug Metab 7:15\u201321","journal-title":"Curr Drug Metab"},{"key":"678_CR29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00003088-200544040-00001","volume":"44","author":"I Mahmood","year":"2005","unstructured":"Mahmood I, Green MD (2005) Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 44:331\u2013347","journal-title":"Clin Pharmacokinet"},{"key":"678_CR30","doi-asserted-by":"crossref","first-page":"F885","DOI":"10.1152\/ajprenal.00123.2002","volume":"284","author":"H Daniel","year":"2003","unstructured":"Daniel H, Rubio-Aliaga I (2003) An update on renal peptide transporters. Am J Renal Physiol 284:F885\u2013F892","journal-title":"Am J Renal Physiol"},{"key":"678_CR31","first-page":"633","volume-title":"Peptides and protein drug analysis","author":"R Braeckman","year":"2000","unstructured":"Braeckman R (2000) Pharmacokinetics and pharmacodynamics of protein therapeutics. In: Reid ER (ed) Peptides and protein drug analysis. Marcel Dekker, New York, pp 633\u2013649"},{"key":"678_CR32","volume-title":"Clinical pharmacokinetics: concepts and applications","author":"M Rowland","year":"1995","unstructured":"Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications, 3rd edn. Lippincott Williams & Wilkins, Philadelphia"},{"key":"678_CR33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2165\/00003088-199732010-00002","volume":"32","author":"YWF Lam","year":"1997","unstructured":"Lam YWF, Banerji S, Hatfield C, Talbert RL (1997) Principles of drug administration in renal insufficiency. Clin Pharmacokinet 32:30\u201357","journal-title":"Clin Pharmacokinet"},{"key":"678_CR34","first-page":"187","volume-title":"Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring","author":"GR Matzke","year":"2006","unstructured":"Matzke GR, Comstock TJ (2006) Influence of renal function and dialysis on drug disposition. In: Burton ME, Shaw LM, Schentag JJ, Evans WE (eds) Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 187\u2013212","edition":"4"},{"key":"678_CR35","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/clpt.1980.94","volume":"27","author":"TP Gibson","year":"1980","unstructured":"Gibson TP, Giacomini KM, Briggs WA et al (1980) Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient. Clin Pharmacol Ther 27:665\u2013670","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR36","first-page":"115","volume-title":"Drug absorption\u2014Proc Edinburgh Int Conf","author":"G Levy","year":"1981","unstructured":"Levy G, Giacomini KM (1981) First-pass effects in health and disease: pharmacokinetics studies on dextropropoxyphene. In: Prescott LF, Nimmo WS (eds) Drug absorption: Proc Edinburgh Int Conf. MTP Press, Lancaster pp 115\u2013122"},{"key":"678_CR37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/00003088-197601050-00004","volume":"1","author":"G Bianchetti","year":"1976","unstructured":"Bianchetti G, Graziani G, Brancacci D et al (1976) Pharmacokinetics and effects of propranolol in terminal uremic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet 1:373\u2013384","journal-title":"Clin Pharmacokinet"},{"key":"678_CR38","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2165\/00003088-199631060-00002","volume":"31","author":"G Davies","year":"1996","unstructured":"Davies G, Kingswood C, Street M (1996) Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 31:410\u2013422","journal-title":"Clin Pharmacokinet"},{"key":"678_CR39","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1046\/j.0306-5251.2001.00029.x","volume":"53","author":"GJ Muirhead","year":"2002","unstructured":"Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouvieux B (2002) The effect of age and renal and hepatic impairment on the Pharmacokinetics of sildenafil citrate. Br J Clin Pharmacol 53:21S\u201330S","journal-title":"Br J Clin Pharmacol"},{"key":"678_CR40","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.ajkd.2003.08.027","volume":"42","author":"MB Kays","year":"2003","unstructured":"Kays MB, Overholser BR, Mueller BA et al (2003) Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis 42:1253\u20131259","journal-title":"Am J Kidney Dis"},{"key":"678_CR41","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2215\/CJN.01580407","volume":"2","author":"PP How","year":"2007","unstructured":"How PP, Fischer JH, Arruda JA et al (2007) Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. Clin J Am Soc Nephrol 2:1235\u20131240","journal-title":"Clin J Am Soc Nephrol"},{"key":"678_CR42","first-page":"82","volume-title":"Applied pharmacokinetics and pharmacodynamics\u2014principles of therapeutic drug monitoring","author":"JJ MacKichan","year":"2006","unstructured":"MacKichan JJ (2006) Influence of protein binding and use of unbound (free) drug concentrations. In: Burton ME, Shaw LM, Schentag JJ, Evans WE (eds) Applied pharmacokinetics and pharmacodynamics\u2014principles of therapeutic drug monitoring. Lippincott Williams, Wilkins, Philadelphia, pp 82\u2013120"},{"key":"678_CR43","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1681\/ASN.V891470","volume":"8","author":"NS Bricker","year":"1997","unstructured":"Bricker NS, Morrin PAF, Kime SW Jr (1997) The pathologic physiology of chronic Bright\u2019s Disease: an exposition of the \u201cintact nephron hypothesis\u201d. J Am Soc Nephrol 8:1470\u20131476","journal-title":"J Am Soc Nephrol"},{"key":"678_CR44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.clpt.2005.10.005","volume":"79","author":"A Periclou","year":"2006","unstructured":"Periclou A, Ventura D, Niranjan R, Abramowitz W (2006) Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 79:134\u2013143","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR45","first-page":"459","volume":"3","author":"LP Balant","year":"1983","unstructured":"Balant LP, Dayer P, Fabre J (1983) Consequences of renal insufficiency on the hepatic clearance of some drugs. Int J Clin Pharmacol Res 3:459\u2013474","journal-title":"Int J Clin Pharmacol Res"},{"key":"678_CR46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0272-6386(86)80148-2","volume":"8","author":"TP Gibson","year":"1986","unstructured":"Gibson TP (1986) Renal disease and drug metabolism. Am J Kidney Dis 8:7\u201317","journal-title":"Am J Kidney Dis"},{"key":"678_CR47","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/bja\/71.2.282","volume":"71","author":"AC Elston","year":"1993","unstructured":"Elston AC, Bayliss MK, Park GR (1993) Effect of renal failure on drug metabolism. Br J Anaesth 71:282\u2013290","journal-title":"Br J Anaesth"},{"key":"678_CR48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0009-9236(03)00056-0","volume":"73","author":"TC Dowling","year":"2003","unstructured":"Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, Henrich WL (2003) Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 73:427\u2013434","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR49","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/sj.clpt.6100148","volume":"81","author":"LA Frassetto","year":"2007","unstructured":"Frassetto LA, Poon S, Tsourounis C, Valera C, Benet LZ (2007) Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther 81:828\u2013832","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR50","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0009-9236(03)00015-8","volume":"73","author":"AW Dreisbach","year":"2003","unstructured":"Dreisbach AW, Japa S, Gebrekal AB, Mowry SE, Lertora JJL, Kamath BL, Rettie AE (2003) Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther 73:475\u2013477 Letter to the Editor","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR51","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2165\/00003088-200847090-00002","volume":"47","author":"S Stehle","year":"2008","unstructured":"Stehle S, Kirchheiner J, Lazar A, Fuhr U (2008) Pharmacogenetics of oral anticoagulants\u2014a basis for dose individualization. Clin Pharmacokinet 47:565\u2013594","journal-title":"Clin Pharmacokinet"},{"key":"678_CR52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clpt.2006.05.006","volume":"80","author":"RF Frye","year":"2006","unstructured":"Frye RF et al (2006) Liver disease Selectivey modulates cytochrome P450- mediated metabolism drugs in liver. Clin Pharmacol Ther 80:235\u2013245","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR53","doi-asserted-by":"crossref","unstructured":"Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147\u20131161","DOI":"10.1007\/s00228-008-0553-z"},{"key":"678_CR54","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/BF00544072","volume":"28","author":"MWE Teunissen","year":"1985","unstructured":"Teunissen MWE, Kampf D, Roots I et al (1985) Antipyrine metabolite formation and excretion in patients with chronic renal insufficiency. Eur J Clin Pharmacol 28:589\u2013595","journal-title":"Eur J Clin Pharmacol"},{"key":"678_CR55","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0090-9556(24)15079-9","volume":"28","author":"FA Leblond","year":"2000","unstructured":"Leblond FA, Giroux L, Villeneuve JP, Pichette V (2000) Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Disp 28:1317\u20131320","journal-title":"Drug Metab Disp"},{"key":"678_CR56","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1681\/ASN.V122326","volume":"12","author":"F Leblond","year":"2001","unstructured":"Leblond F, Gu\u00e9vin C, Demers C, Pellerin I, Gascon-Barr\u00e9 M, Pichette V (2001) Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12:326\u2013332","journal-title":"J Am Soc Nephrol"},{"key":"678_CR57","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/01.ASN.0000017575.50319.77","volume":"13","author":"FA Leblond","year":"2002","unstructured":"Leblond FA, Petrucci M, Dub\u00e9 P, Bernier G, Bonnardeaux A, Pichette V (2002) Downregulation of intestinal cytochrome P450 in chronic renal failure. J Am Soc Nephrol 13:1579\u20131585","journal-title":"J Am Soc Nephrol"},{"key":"678_CR58","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/sj.bjp.0704951","volume":"137","author":"C Gu\u00e9vin","year":"2002","unstructured":"Gu\u00e9vin C, Michaud J, Naud J, Leblond FA, Pichette V (2002) Down-regulation of hepatic cytochrome P450 in chronic renal failure: the role of uremic mediators. Br J Pharmacol 137:1039\u20131046","journal-title":"Br J Pharmacol"},{"key":"678_CR59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1389200033489532","volume":"4","author":"V Pichette","year":"2003","unstructured":"Pichette V, Leblond FA (2003) Drug metabolism in chronic renal failure. Curr Drug Metab 4:91\u2013103","journal-title":"Curr Drug Metab"},{"key":"678_CR60","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1124\/dmd.104.000521","volume":"32","author":"H Sun","year":"2004","unstructured":"Sun H, Huang Y, Frassetto L, Benet LZ (2004) Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Disp 32:1239\u20131246","journal-title":"Drug Metab Disp"},{"key":"678_CR61","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/sj.bjp.0706138","volume":"144","author":"J Michaud","year":"2005","unstructured":"Michaud J, Dub\u00e9 P, Naud J, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V (2005) Effects of serum from patients with chronic renal failure on rat heaptic cytochrome P450. Br J Pharmacol 144:1067\u20131077","journal-title":"Br J Pharmacol"},{"key":"678_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.05.010","volume":"109","author":"H Sun","year":"2006","unstructured":"Sun H, Frassetto L, Benet LZ (2006) Effects of renal failure on drug transport and metabolism. Pharmacol Ther 109:1\u201311","journal-title":"Pharmacol Ther"},{"key":"678_CR63","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1681\/ASN.2006010035","volume":"17","author":"J Michaud","year":"2006","unstructured":"Michaud J, Naud J, Chouinard J, D\u00e9sy F, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V (2006) Role of parathyroid hormone in the down-regulation of liver cytochrome P450 in chronic renal failure. J A Soc Nephrol 17:3041\u20133048","journal-title":"J A Soc Nephrol"},{"key":"678_CR64","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/clpt.2008.59","volume":"83","author":"TD Nolin","year":"2008","unstructured":"Nolin TD, Naud J, Leblond FA, Pichette V (2008) Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 83:898\u2013903","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR65","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1681\/ASN.2007090974","volume":"19","author":"E Simard","year":"2008","unstructured":"Simard E, Naud J, Michaud J, Leblond FA, Bonnardeaux A, Guillemette C, Sim E, Pichette V (2008) Downregulation of hepatic acetylation of drugs in chronic renal failure. J Am Soc Nephrol 19:1352\u20131359","journal-title":"J Am Soc Nephrol"},{"key":"678_CR66","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/dmd.105.006601","volume":"34","author":"C Yu","year":"2006","unstructured":"Yu C, Ritter JK, Krieg RJ, Rege B, Karnes TH, Sarkar MA (2006) Effect of chronic renal insufficiency on hepatic and renal UDP- glucuronyltransferases in rats. Drug Metab Disp 34:621\u2013627","journal-title":"Drug Metab Disp"},{"key":"678_CR67","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1681\/ASN.2006060610","volume":"17","author":"TD Nolin","year":"2006","unstructured":"Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J (2006) Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 17:2363\u20132367","journal-title":"J Am Soc Nephrol"},{"key":"678_CR68","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0163-7258(91)90065-T","volume":"51","author":"JO Miners","year":"1991","unstructured":"Miners JO, Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51:347\u2013369","journal-title":"Pharmacol Ther"},{"key":"678_CR69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0009-2797(03)00020-6","volume":"145","author":"MJ Bailey","year":"2003","unstructured":"Bailey MJ, Dickinson RG (2003) Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact 145:117\u2013137","journal-title":"Chem Biol Interact"},{"key":"678_CR70","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0090-9556(25)07843-2","volume":"10","author":"RK Verbeeck","year":"1982","unstructured":"Verbeeck RK (1982) Glucuronidation and disposition of drug glucuronides in patients with renal failure. Drug Metab Disp 10:87\u201389","journal-title":"Drug Metab Disp"},{"key":"678_CR71","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/03009748109095297","volume":"10","author":"G Stafanger","year":"1981","unstructured":"Stafanger G, Larson HW, Hansen H, Sorensen K (1981) Pharmacokinetics of ketoprofen in patients with chronic renal failure. Scand J Rheumatol 10:189\u2013192","journal-title":"Scand J Rheumatol"},{"key":"678_CR72","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2125.1996.03864.x","volume":"42","author":"KJ Skeith","year":"1996","unstructured":"Skeith KJ, Dasgupta M, Lange R, Jamali F (1996) The influence of renal function on the pharmacokinetics of unchanged and acyl- glucuronide ketoprofen enantiomers after 50 and 100\u00a0mg racemic ketoprofen. Br J Clin Pharmacol 42:163\u2013169","journal-title":"Br J Clin Pharmacol"},{"key":"678_CR73","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1365-2125.1999.00046.x","volume":"48","author":"NG Grubb","year":"1999","unstructured":"Grubb NG, Rudy DW, Brater DC, Hall SD (1999) Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a \u2018futile cycle\u2019 of elimination. Br J Clin Pharmacol 48:494\u2013500","journal-title":"Br J Clin Pharmacol"},{"key":"678_CR74","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1600-0773.1988.tb00965.x","volume":"63","author":"QY Yue","year":"1988","unstructured":"Yue QY, Odar-Cederl\u00f6f I, Svensson JO, S\u00e4we J (1988) Glucuronidation of morphine in human kidney microsomes. Pharmacol Toxicol 63:337\u2013341","journal-title":"Pharmacol Toxicol"},{"key":"678_CR75","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s002280050074","volume":"50","author":"AA Raoof","year":"1996","unstructured":"Raoof AA, Van Obbergh LJ, de Ville de Goyet J, Verbeeck RK (1996) Extrahepatic metabolism of propofol in man: possible contribution of gut wall and kidney. Eur J Clin Pharmacol 50:91\u201396","journal-title":"Eur J Clin Pharmacol"},{"key":"678_CR76","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0006-2952(97)00534-0","volume":"55","author":"KA McGurk","year":"1998","unstructured":"McGurk KA, Brierley CH, Burchell B (1998) Drug glucuronidation by human reanl UDP-glucuronosyltransferases. Biochem Pharmacol 55:1005\u20131012","journal-title":"Biochem Pharmacol"},{"key":"678_CR77","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/clpt.1990.203","volume":"48","author":"JX Mazoit","year":"1990","unstructured":"Mazoit JX, Sandouk P, Scherrmann JM, Roche A (1990) Extrahepatic metabolism of morphine occurs in humans. Clin Pharmacol Ther 48:613\u2013618","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR78","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1177\/106002809202601116","volume":"26","author":"TB Vree","year":"1992","unstructured":"Vree TB, Hekster YA, Anderson PG (1992) Contribution of the human kidney to the metabolic clearance of drugs. Ann Pharmacother 26:1421\u20131428","journal-title":"Ann Pharmacother"},{"key":"678_CR79","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2125.2005.02393.x","volume":"60","author":"H Hiraoka","year":"2005","unstructured":"Hiraoka H, Yamamoto K, Miyoshi S, Morita T, Nakamura K, Kadoi Y, Kunimoto F, Horiuchi R (2005) Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain. Br J Clin Pharmacol 60:176\u2013182","journal-title":"Br J Clin Pharmacol"},{"key":"678_CR80","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2125.1984.tb02451.x","volume":"18","author":"GA Verpooten","year":"1984","unstructured":"Verpooten GA, Verbist L, Buntinx AP, Entwistle LA, Jones KH, De Broe ME (1984) The pharmacokinetics of imipenem (thienamycin- formamidine) and the renal dehydropeptidase inhibitor cilastin sodium in normal subjects and patients with renal failure. Br J Clin Pharmacol 18:183\u2013193","journal-title":"Br J Clin Pharmacol"},{"key":"678_CR81","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clpt.2005.05.011","volume":"78","author":"RH Ho","year":"2005","unstructured":"Ho RH, Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260\u2013277","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR82","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2174\/1389200033489389","volume":"4","author":"LZ Benet","year":"2003","unstructured":"Benet LZ, Cummins CL, Wu CY (2003) Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 4:393\u2013398","journal-title":"Curr Drug Metab"},{"key":"678_CR83","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","volume":"22","author":"CY Wu","year":"2005","unstructured":"Wu CY, Benet LZ (2005) Predicting drug disposition via application of BCS: transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11\u201323","journal-title":"Pharm Res"},{"key":"678_CR84","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1124\/dmd.106.009258","volume":"34","author":"JL Lam","year":"2006","unstructured":"Lam JL, Okochi H, Huanh Y, Benet LZ (2006) In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism characterizing the importance of transporter-enzyme interplay. Drug Metab Disp 34:1336\u20131344","journal-title":"Drug Metab Disp"},{"key":"678_CR85","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.clpt.6100038","volume":"81","author":"YY Lau","year":"2007","unstructured":"Lau YY, Huang Y, Frassetto L, Benet LZ (2007) Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194\u2013204","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR86","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1124\/jpet.106.112631","volume":"320","author":"J Naud","year":"2007","unstructured":"Naud J, Michaud J, Boisvert C, Desbiens K, Leblod FA, Mitchell A, Jones C, Bonnardeaux A, Pichette V (2007) Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther 320:978\u2013985","journal-title":"J Pharmacol Exp Ther"},{"key":"678_CR87","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/dmd.107.018192","volume":"36","author":"J Naud","year":"2008","unstructured":"Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V (2008) Effects of chronic renal failure on liver drug transporters. Drug Metab Disp 36:124\u2013128","journal-title":"Drug Metab Disp"},{"key":"678_CR88","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1159\/000189456","volume":"74","author":"T Niwa","year":"1996","unstructured":"Niwa T, Miyazaki T, Katsuzaki T, Tatemichi N, Takei Y (1996) Serum levels of 3-deoxyglucosoneand tissue contents of advanced glycation end-products are increased in streptozotocin-induced diabetic rats with nephropathy. Nephron 74:580\u2013585","journal-title":"Nephron"},{"key":"678_CR89","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.1046\/j.1523-1755.2001.07831.x","volume":"78","author":"R Dzurik","year":"2001","unstructured":"Dzurik R, Spustova V, Krivosikova Z, Gazdikova K (2001) Hippurate participates in the correction of metabolic acidosis. Kidney Int Suppl 78:S278\u2013S281","journal-title":"Kidney Int Suppl"},{"key":"678_CR90","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/01.ftd.0000183384.89275.f4","volume":"27","author":"M Gusella","year":"2005","unstructured":"Gusella M, Rebeschini M, Cartel G, Ferrazzi E, Ferrari M, Padrini R (2005) Effect of hemodialysis on the metabolic clearance of 5-fluorouracil in a patient with end-stage renal failure. Ther Drug Monit 27:816\u2013818","journal-title":"Ther Drug Monit"},{"key":"678_CR91","doi-asserted-by":"crossref","unstructured":"Michaud J, Nolin TD, Naud J, Dani M, Lafrance JP, Leblond FA, Himmelfarb J and Pichette V (2008) Effect of hemodialysis on hepatic Cytochrome P450 functional expression. J Pharmacol Sci 108(2):157\u2013163","DOI":"10.1254\/jphs.08042FP"},{"key":"678_CR92","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-198106050-00001","volume":"6","author":"RK Verbeeck","year":"1981","unstructured":"Verbeeck RK, Branch RA, Wilkinson GR (1981) Drug metabolites in renal failure: pharmacokinetics and clinical implications. Clin Pharmacokinet 6:329\u2013345","journal-title":"Clin Pharmacokinet"},{"key":"678_CR93","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0140-6736(84)90323-4","volume":"ii","author":"H McQuay","year":"1984","unstructured":"McQuay H, Moore A (1984) Be aware of renal function when prescribing morphine. Lancet ii:284\u2013285","journal-title":"Lancet"},{"key":"678_CR94","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/bmj.292.6535.1548","volume":"292","author":"R Osborne","year":"1986","unstructured":"Osborne R, Joel SP, Slevin ML (1986) Morphine intoxication in renal insufficiency: the role of morphine-6-glucuronide. Br Med J 292:1548\u20131549","journal-title":"Br Med J"},{"key":"678_CR95","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF00543973","volume":"32","author":"J S\u00e4we","year":"1987","unstructured":"S\u00e4we J, Odar-Cederl\u00f6f I (1987) Kinetics of morphine in patients with renal failure. Eur J Clin Pharmacol 32:377\u2013382","journal-title":"Eur J Clin Pharmacol"},{"key":"678_CR96","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.1993.127","volume":"54","author":"R Osborne","year":"1993","unstructured":"Osborne R, Joel S, Grebenik K, Trew D, Slevin M (1993) The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 54:158\u2013167","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR97","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/0024-3205(87)90431-0","volume":"41","author":"GW Pasternak","year":"1987","unstructured":"Pasternak GW, Bodnar RJ, Clark JA, Interrusi CE (1987) Morphine-6-glucuronide, a potent mu agonist. Life Sci 41:2845\u20132849","journal-title":"Life Sci"},{"key":"678_CR98","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1067\/mcp.2000.111934","volume":"68","author":"RT Penson","year":"2000","unstructured":"Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML (2000) Randomized placebo-controlled trial of activity of the morphine glucuronides. Clin Pharmacol Ther 68:667\u2013676","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR99","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5055\/jom.2005.0021","volume":"1","author":"RT Penson","year":"2005","unstructured":"Penson RT, Joel SP, Gloyne A, Clark S, Slevin ML (2005) Morphine analgesia in cancer pain: role of the glucuronides. J Opioid Manag 1:83\u201390","journal-title":"J Opioid Manag"},{"key":"678_CR100","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00228-007-0329-x","volume":"63","author":"O Dale","year":"2007","unstructured":"Dale O, Thoner J, Nilsen T, Tveita T, Borchgrevink PC, Klepstad P (2007) Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery. Eur J Clin Pharmacol 63:837\u2013842","journal-title":"Eur J Clin Pharmacol"},{"key":"678_CR101","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00000542-199407000-00013","volume":"81","author":"G D\u2019Honneur","year":"1994","unstructured":"D\u2019Honneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P (1994) Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morhine. Anesthesiology 81:87\u201393","journal-title":"Anesthesiology"},{"key":"678_CR102","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1471-4159.2002.01177.x","volume":"83","author":"J L\u00f6tsch","year":"2002","unstructured":"L\u00f6tsch J, Schmidt R, Vetter G, Schmidt H, Niederberger E, Geisslinger G, Tegeder I (2002) Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J Neurochem 83:241\u2013248","journal-title":"J Neurochem"},{"key":"678_CR103","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1046\/j.1471-4159.2003.01990.x","volume":"86","author":"F Bourasset","year":"2003","unstructured":"Bourasset F, Cisternino S, Temsamani J, Scherrmann JM (2003) Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain-barrier. J Neurochem 86:1564\u20131567","journal-title":"J Neurochem"},{"key":"678_CR104","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/00000542-200210000-00011","volume":"97","author":"J L\u00f6tsch","year":"2002","unstructured":"L\u00f6tsch J, Zimmermann M, Darimont J, Marx C, Dudziak R, Skarke C, Geisslinger G (2002) Does the A118G polymorphism at the \u00b5-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology 97:814\u2013819","journal-title":"Anesthesiology"},{"key":"678_CR105","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1525-1594.1995.tb02272.x","volume":"19","author":"C Woffindin","year":"1995","unstructured":"Woffindin C, Hoenich NA (1995) Hemodialyzer performance: a review of the trends over the past two decades. Artif Organs 19:1113\u20131119","journal-title":"Artif Organs"},{"key":"678_CR106","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.ki.5002634","volume":"108","author":"J Gjessing","year":"2008","unstructured":"Gjessing J (2008) Studies on peritoneal dialysis. Kidney Int Suppl 108:S18\u2013S25","journal-title":"Kidney Int Suppl"},{"key":"678_CR107","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10047-004-0257-9","volume":"7","author":"T Fujimura","year":"2004","unstructured":"Fujimura T, Uchi Y, Fukuda M, Miyazaki M, Uezumi S, Hiyoshi T (2004) Development of a dialyzer with enhanced internal filtration to increase the clearance of low molecular weight proteins. J Artif Organs 7:149\u2013153","journal-title":"J Artif Organs"},{"key":"678_CR108","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/039139880402700511","volume":"27","author":"L Lucchi","year":"2004","unstructured":"Lucchi L, Fiore GB, Guadagni G, Perrone S, Malaguti V, Caruso F, Fumero R, Albertazzi A (2004) Clinical evaluation of internal hemodiafiltration (iHDF): a diffusive-convective technique performed with internal filtration enhanced high-fluc dialyzers. Int J Artif Organs 27:414\u2013419","journal-title":"Int J Artif Organs"},{"key":"678_CR109","unstructured":"FDA Guidance for Industry (1998) Pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing and labelling. Available at: http:\/\/www.fda.gov\/cder\/guidance\/1449fnl.pdf"},{"key":"678_CR110","unstructured":"EMEA (2004) Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. Available at: http:\/\/www.emea.europa.eu\/pdfs\/human\/ewp\/022502en.pdf"},{"key":"678_CR111","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/978-0-585-36947-1_30","volume-title":"Replacement of Renal Function by Dialysis","author":"TA Golper","year":"1996","unstructured":"Golper TA, Marx MA, Shuler C et al (1996) Drug dosage in dialysis patients. In: Jacobs C, Kjellstrand CM, Koch KM (eds) Replacement of Renal Function by Dialysis. Kluwer, Boston, pp 750\u2013614"},{"key":"678_CR112","unstructured":"Aronoff GR, Bennett WM, Berns JS et al (2007) DrugpPrescribing in renal failure: dosing guidelines for adults and children, 5th edn. American College of Physicians, Philadelphia"},{"key":"678_CR113","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2125.2007.02963.x","volume":"64","author":"A Asari","year":"2007","unstructured":"Asari A, Iles-Smith H, Chen Y-C, Naderer O, Johnson MA, Yuen GJ, Otto V, Dunn JA, Gokal R (2007) Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure. Br J Clin Pharmacol 64:738\u2013744","journal-title":"Br J Clin Pharmacol"},{"key":"678_CR114","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.ackd.2007.03.004","volume":"14","author":"BS Decker","year":"2007","unstructured":"Decker BS, Mueller BA, Sowinski KM (2007) Drug dosing considerations in alternative hemodialysis. Adv Chronic Kidney Dis 14:17\u201326","journal-title":"Adv Chronic Kidney Dis"},{"key":"678_CR115","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2215\/CJN.02920707","volume":"3","author":"KM Sowinski","year":"2008","unstructured":"Sowinski KM, Magner SJ, Lucksiri A, Scott MK, Hamburger MJ, Mueller BA (2008) Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol 3:355\u2013361","journal-title":"Clin J Am Soc Nephrol"},{"key":"678_CR116","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00003088-199018050-00004","volume":"18","author":"LL Ponto","year":"1990","unstructured":"Ponto LL, Schoenwald RD (1990) Furosemide (frusemide): a pharmacokinetic\/pharmacodynamic review (part I). Clin Pharmacokinet 18:381\u2013408","journal-title":"Clin Pharmacokinet"},{"key":"678_CR117","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/clpt.1986.151","volume":"40","author":"DC Brater","year":"1986","unstructured":"Brater DC, Anderson SA, Brown-Cartwright D (1986) Response to furosemide in chronic renal insufficiency: rationale for limited doses. Clin Pharmacol Ther 40:134\u2013139","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR118","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0049-3848(02)00031-2","volume":"105","author":"GJ Sanderink","year":"2002","unstructured":"Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX (2002) Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4\u00a0days in patients with renal impairment. Thromb Res 105:225\u2013231","journal-title":"Thromb Res"},{"key":"678_CR119","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00007691-200406000-00015","volume":"26","author":"JS Hulot","year":"2004","unstructured":"Hulot JS, Vantelon C, Urien S, Bouzamondo A, Mah\u00e9 I, Ankri A, Montalescot G, Lechat P (2004) Effect of renal failure on the pharmacokinetics of enoxaparin and consequences on dose adjustment. Ther Drug Monit 26:305\u2013310","journal-title":"Ther Drug Monit"},{"key":"678_CR120","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood.V94.8.2569.420k13_2569_2574","volume":"94","author":"M Noris","year":"1999","unstructured":"Noris M, Remuzzi G (1999) Uremic bleeding: closing the circle after 30\u00a0years of controversies? Blood 94:2569\u20132574","journal-title":"Blood"},{"key":"678_CR121","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1542-4758.2007.00166.x","volume":"11","author":"KG Fischer","year":"2007","unstructured":"Fischer KG (2007) Essentials of anticoagulation in hemodialysis. Hemodial Int 11:178\u2013189","journal-title":"Hemodial Int"},{"key":"678_CR122","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2165\/00002018-200730110-00001","volume":"30","author":"DF Brophy","year":"2007","unstructured":"Brophy DF, Sica DA (2007) Use of enoxaparin in patients with chronic kidney disease: safety considerations. Drug Saf 30:991\u2013994","journal-title":"Drug Saf"},{"key":"678_CR123","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2165\/00003088-200342120-00003","volume":"42","author":"J Fareed","year":"2003","unstructured":"Fareed J, Hoppensteadt D, Walnga J, Iqbal O, Ma Q, Jeske W, Sheikh T (2003) Pharmacodynamic and harmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet 42:1043\u20131057","journal-title":"Clin Pharmacokinet"},{"key":"678_CR124","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2165\/00003088-200847110-00001","volume":"48","author":"M Edholm","year":"2008","unstructured":"Edholm M, Berglund EG, Salmonson T (2008) Regulatory aspects of pharmacokinetic profiling in special populations. Clin Pharmacokinet 48:693\u2013701","journal-title":"Clin Pharmacokinet"},{"key":"678_CR125","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/clpt.2008.208","volume":"85","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Zhang L, Abraham S, Apparaju S, Wu T-C, Strong JM, Xiao S, Atkinson AJ Jr, Thummel KE, Leeder JS, Lee C, Burckart GJ, Lesko LJ, Huang S-M (2009) Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther 85:305\u2013311","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR126","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/clpt.1992.47","volume":"51","author":"C Peck","year":"1992","unstructured":"Peck C, Barr W, Benet L et al (1992) Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. Clin Pharmacol Ther 51:465\u2013473","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR127","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF00191898","volume":"46","author":"L Aarons","year":"1994","unstructured":"Aarons L, Balant LP, Mentr\u00e9 F et al (1994) Population approaches in drug development: report on an expert meeting to discuss population pharmacokinetic\/pharmacodynamic software. Eur J Clin Pharmacol 46:389\u2013391","journal-title":"Eur J Clin Pharmacol"},{"key":"678_CR128","unstructured":"FDA Guidance for Industry (1999) Population pharmacokinetics. Available at: http:\/\/www.fda.gov\/cder\/guidance\/1852fnl.pdf"},{"key":"678_CR129","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00003088-200847050-00004","volume":"47","author":"N Toublanc","year":"2008","unstructured":"Toublanc N, Sargentini-Maier ML, Lacroix B, Jacqmin P, Stockis A (2008) Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. Clin Pharmacokinet 47:333\u2013341","journal-title":"Clin Pharmacokinet"},{"key":"678_CR130","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003088-200847080-00001","volume":"47","author":"AS Zandvliet","year":"2008","unstructured":"Zandvliet AS, Schellens JHM, Beijnen JH, Huitema ADR (2008) Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. Clin Pharmacokinet 47:487\u2013513","journal-title":"Clin Pharmacokinet"},{"key":"678_CR131","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1185\/03007990802312807","volume":"24","author":"TB Tzeng","year":"2008","unstructured":"Tzeng TB, Schneck DW, Birmingham BK, Mitchell PD, Zhang H, Martin PD, Kung LP (2008) Population pharmacokinetics of rosuvastatin: implications of renal impairment, race and dyslipidaemias. Curr Med Res Opin 24:2575\u20132585","journal-title":"Curr Med Res Opin"},{"key":"678_CR132","unstructured":"Food and Drug Administration (2004) Enoxaparin injection drug approval. Available at: www.fda.gov\/medwatch\/SAFETY\/2004\/lovenox_PI.pdf"},{"key":"678_CR133","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.clpt.2005.02.012","volume":"77","author":"J-S Hulot","year":"2005","unstructured":"Hulot J-S, Montalescot G, Lechat P, Collet J-P, Ankri A, Urien S (2005) Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 77:542\u2013552","journal-title":"Clin Pharmacol Ther"},{"key":"678_CR134","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/bmj.38476.471088.3A","volume":"331","author":"L Vidal","year":"2005","unstructured":"Vidal L, Shavit M, Fraser A, Paul M, Leibovici L (2005) Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. Br Med J 331:263\u2013266","journal-title":"Br Med J"},{"key":"678_CR135","volume-title":"British national formulary","author":"JF Committee","year":"2004","unstructured":"Committee JF (2004) British national formulary, 48th edn. London, British Medical Association and Royal Pharmaceutical Society of Great Britain, London","edition":"48"},{"key":"678_CR136","unstructured":"Sweetman SC (ed) (2004) Martindale; the complete drug reference. Pharmaceutical Press, London"},{"key":"678_CR137","unstructured":"McEvoy GK, Miller J, Snow EK, Welsh OH, Litvak K (eds) (2004) American hospital (AHFS) drug information. American Society of Health-System Pharmacists, Bethesda"},{"key":"678_CR138","unstructured":"Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I et al (eds) (1999) Drug prescribing in renal failure: dosing guidelines for adults (1999) American College of Physicians, Philadelphia"},{"key":"678_CR139","first-page":"292","volume":"331","author":"Letters to the Editor","year":"2005","unstructured":"Letters to the Editor (2005) Dose adjustment in renal impairment. Br Med J 331:292\u2013294","journal-title":"Br Med J"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0678-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-009-0678-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0678-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T01:49:22Z","timestamp":1739152162000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-009-0678-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,20]]},"references-count":139,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["678"],"URL":"https:\/\/doi.org\/10.1007\/s00228-009-0678-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,20]]}}}